Business Context and Reporting Period
Company: CURIS, INC. (CRIS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended September 30, 2024
Business Overview: Curis is a biotechnology company focused on developing emavusertib, an IRAK4 inhibitor for hematologic malignancies. The company also holds a collaboration with Genentech/Roche for the commercialization of Erivedge (vismodegib), which generates royalty revenue. In May 2024, the company streamlined operations, reducing its workforce by approximately 30% to focus on key clinical trials.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenues, net | $2,931 | $2,833 | $7,563 | $7,327 |
| Net Loss | $(10,092) | $(12,181) | $(33,771) | $(35,701) |
| Net Loss Per Share (Basic/Diluted) | $(1.70) | $(2.13) | $(5.77) | $(6.96) |
| Cash and Cash Equivalents (Sept 30, 2024) | $20,854 | |||
| Total Assets (Sept 30, 2024) | $42,473 | |||
| Total Liabilities (Sept 30, 2024) | $51,208 | |||
| Stockholders' Equity (Deficit) | $(8,735) | |||
| Cash Used in Operating Activities (9M) | $30,303 | $28,248 |
Note: The company has an accumulated deficit of $1.23 billion as of September 30, 2024.
Material Changes vs. Prior Period
- Revenue: Net revenue increased slightly by 3% ($0.1 million) in Q3 2024 compared to Q3 2023, driven by royalties from Erivedge sales.
- Operating Expenses:
- R&D: Decreased 6% in Q3 2024 ($9.7M vs $10.4M) due to lower consulting and employee costs following workforce reductions.
- G&A: Decreased 21% in Q3 2024 ($3.8M vs $4.8M) primarily due to lower legal and employee-related costs.
- Liquidity: Cash and cash equivalents decreased from $26.7 million at year-end 2023 to $20.9 million at September 30, 2024. Short-term investments were fully liquidated or matured by the end of the period.
- Financing: In October 2024 (subsequent to period end), the company completed a registered direct offering and private placement of warrants, raising approximately $10.8 million in net proceeds.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has identified conditions raising substantial doubt about the company's ability to continue as a going concern within one year of the filing date. Current cash ($20.9M) plus recent financing ($10.8M) is projected to fund operations only into mid-2025.
- Clinical Pipeline: Focus remains on the TakeAim Leukemia and TakeAim Lymphoma Phase 1/2 studies for emavusertib, as well as the AML Triplet study. Additional data is expected in December 2024 and Q1 2025.
- Royalty Liability: The company has a significant liability related to the sale of future royalties (Oberland Purchase Agreement). As of September 30, 2024, the estimated Put/Call Price is $41.0 million. The company disputes allegations of default made by the Purchasers in March 2023, but a failure to defend these claims could materially impact the business.
- Capital Needs: The company will require substantial additional capital to fund clinical trials and operations. Failure to raise funds could force delays or elimination of development programs.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $10.8 million raised in October 2024 combined with existing cash to fund operations through mid-2025.
- Going Concern Status: Review the specific conditions cited in Note 1 regarding the substantial doubt about the company's ability to continue as a going concern.
- Oberland Dispute: Monitor the status of the alleged default under the Oberland Purchase Agreement and the potential $41.0 million repurchase obligation.
- Clinical Milestones: Track the release of data from the TakeAim Leukemia and Lymphoma studies expected in late 2024 and early 2025.
- Future Financing: Assess the likelihood and terms of future equity financings or strategic collaborations required to sustain operations beyond mid-2025.